SCHEMBL256768

SCHEMBL256768

O=C(c1ccccc1)c1ccc(Br)cn1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.63
KDM4E B2RXH2 2/20 0.63
KMT2A Q03164 5/20 0.56
ALOX15 P16050 1/20 0.50
HTT P42858 1/20 0.50
CNR2 P34972 1/20 0.47
MAPT P10636 4/20 0.46
POLB P06746 1/20 0.46
RAB9A P51151 5/20 0.45
MEN1 O00255 4/20 0.45
NPC1 O15118 4/20 0.45
RXFP1 Q9HBX9 1/20 0.45
AKR1C3 P42330 1/20 0.44
P4HTM Q9NXG6 2/20 0.42
PTGDR2 Q9Y5Y4 1/20 0.42
P4HA1 P13674 1/20 0.41
MIF P14174 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
PKM P14618 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15260257 0.83 ALDH1A1 (0.51) ALDH1A1KDM4EKMT2AMAPTPOLB
SCHEMBL27296576 0.82 KDM4E (0.55) ALDH1A1KDM4EKMT2APOLBRAB9A
SCHEMBL3033377 0.82 KDM4E (0.55) ALDH1A1KDM4EKMT2ACNR2MAPT
SCHEMBL13606933 0.82 ALDH1A1 (0.55) ALDH1A1KDM4EKMT2AHTTMAPT
SCHEMBL17157509 0.80 KDM4E (0.56) ALDH1A1KDM4EKMT2AALOX15HTT
SCHEMBL238537 0.79 LTC4S (0.51) ALDH1A1KDM4EKMT2APOLBAKR1C3
SCHEMBL5260070 0.78 RAB9A (0.65) ALDH1A1KDM4EKMT2AALOX15HTT
SCHEMBL157288 0.78 KDM4E (1.00) ALDH1A1KDM4EKMT2AALOX15HTT
SCHEMBL20104370 0.78 KMT2A (0.56) ALDH1A1KDM4EKMT2AHTTCNR2
SCHEMBL20104422 0.78 KMT2A (0.56) ALDH1A1KDM4EKMT2ACNR2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024008909-A1 INHIBITORS OF CORONAVIRUS JANSSEN PHARMACEUTICA NV (BE) 2024-01-11 WO disclosed
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
EP-2612848-A1 CYCLIC AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-07-10 EP disclosed
WO-2012029942-A1 CYCLIC AMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE HDAC10, H1-10, H1-0 ALDH1A1 538/4885KDM4E 2413/4885KMT2A 1199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.